Study emphasises need for improved healthcare infrastructure for villages near Mudumalai Tiger Reserve
A recent study conducted by the Bengaluru-based Centre for Wildlife Studies (CWS) in 35 villages near the Mudumalai Tiger Reserve (MTR) in Tamil Nadu emphasises the urgent need for improved healthcare infrastructure, including access to clean water, sanitation, and health insurance coverage for the marginalised populations living there.
The research study, titled 'Knowledge, attitudes, and practices related to health and well-being in a forest fringe community in southern India', published in BMC Public Health, draws on data collected between 2021 and 2022 through semi-structured interviews in 322 households across 35 villages near MTR.
'This research study reveals that healthcare practices in these rural communities are influenced by a complex interaction of environmental, social, and cultural factors. In villages located within the core zone of the MTR, there is a marked reliance by people on traditional knowledge and practices for preventing and treating health conditions. Despite lower levels of formal education, these communities demonstrate a high degree of awareness of health risks, particularly regarding lifestyle-related chronic diseases. However, they were less aware of risks from zoonotic and vector-borne diseases,' according to CWS.
Respondents self-reported a mix of chronic (62%) and acute (31%) health issues, with undiagnosed fever being the most reported acute ailment (57%).
Chronic conditions, such as cardiovascular diseases and diabetes, were reported by 62% of respondents and were more prevalent in villages in the buffer and boundary zones that are closer to urban areas.
'While our study population seemed to suffer mainly from lifestyle-related chronic illnesses, the low self-reported incidences of tuberculosis, a chronic disease with high national prevalence, and sickle cell anemia, a genetic disorder with high prevalence in tribal populations of southern India, were unexpected findings that need deeper investigation,' said Dr. Bindu Raghavan, lead author of the study.
'A key insight is the community's reliance on a wide range of healthcare options. The study found that 63% of respondents preferred government healthcare services for primary care, while 30% opted for private facilities for surgical procedures. Education levels were a key determinant in healthcare access, with individuals with higher education being more likely to utilise clinical healthcare services. Meanwhile, those with lower education levels often turned to traditional healers or avoided medical care altogether,' according to CWS.
According to the study, a majority (76%) expressed satisfaction with public services, citing dignified treatment (64%) and regular visits from healthcare workers as reasons for seeking care.
The study also identifies systemic barriers that hinder healthcare access, such as inadequate infrastructure.
'For instance, 15% of respondents reported spending more than a month's income on healthcare services. Furthermore, marginalised groups, particularly women and low-income households, face additional challenges in accessing healthcare, exacerbating health disparities in these communities,' according to CWS.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Time of India
an hour ago
- Time of India
Dr Reddy's, Alvotech join hands to co-develop, manufacture & commercialise biosimilar of Merck's blockbuster drug Keytruda
Dr Reddy's, Alvotech join hands to co-develop, manufacture & commercialise biosimilar of Merck's blockbuster drug Keytruda HYDERABAD: Dr Reddy's Laboratories has entered into a collaboration and license agreement with Iceland-based biotech player Alvotech for the co-development, manufacturing and commercialiation of a biosimilar of Merck Sharp & Dohme's blockbuster drug Keytruda (pembrolizumab). Keytruda, which is used for the treatment of various types of cancer, clocked sales of over US$29.5 billion in 2024. The collaboration will combine Dr Reddy's and Alvotech's capabilities in biosimilars to speed up the development process and extend the global reach of the biosimilar candidate. As per the agreement, the two companies will share the costs and responsibilities for jointly developing and manufacturing the biosimilar candidate and subject to certain exceptions, each company will have the right to commercialise the product globally, Dr Reddy's said on Thursday. 'The agreement demonstrates Alvotech's ability to leverage its dedicated R&D and manufacturing platform for biosimilars, accelerating the expansion of our pipeline by pursuing growing global markets. It further enables us to increase the availability of cost-effective, critical biologic medications to patients worldwide,' said Róbert Wessman, chairman & CEO, Alvotech. Dr Reddy's CEO, Erez Israeli, said the pact demonstrates the company's ability to develop and manufacture high-quality and affordable treatment options for patients worldwide. 'Oncology has been a top focus therapy area for us, and this collaboration will further enhance our capabilities in oncology, as pembrolizumab currently represents one of the most critical therapies in immuno-oncology,' Israeli added. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now


Time of India
an hour ago
- Time of India
Ernakulam schools hold sessions on life skills, wellness sessions
Kochi: Schools across Ernakulam district launched this academic year with sessions focusing on life skills and student well-being. They have dedicated an hour daily during the first two weeks for sessions on health, hygiene, nutrition and anti-drug awareness. Tired of too many ads? go ad free now "Familiarization week began with students sharing their vacation experiences and exploring school facilities. Each day, we dedicate an hour to life skills to support their emotional and social development," said Govt High School, Edappally, headmistress Minimol V V. According to Minimol, apart from the two-week sessions on life skills, the school will conduct Zumba dance sessions throughout the academic year to ensure student wellness. According to Ramamangalam High School social science teacher Anoob John, key topics to be covered in the sessions include road safety, digital discipline, resource conservation and school property care. "Activities such as role-playing, visual aids and poster-making are being used to enhance student engagement," said John. Simultaneously, district is witnessing a technological transformation in classrooms, led by Kerala Infrastructure and Technology for Education (KITE). The agency is introducing artificial intelligence (AI) and robotics in schools, enhancing the state's push toward digital learning. As part of this initiative, KITE distributed Arduino-based robotics kits to 270 high schools in both aided and unaided sectors. Teacher training and infrastructure development are also under way to support AI-based curriculum integration.
&w=3840&q=100)

Business Standard
2 hours ago
- Business Standard
Wockhardt eyes $9 bn market opportunity for novel antibiotic Zaynich
Mumbai-based pharmaceutical major Wockhardt, which is set to launch a new class of antibiotic, Zaynich, in India this year, estimates a total addressable market opportunity of $9 billion. This includes a $7-billion market in the US and Europe, and a ₹17,000-crore opportunity in India. The company's stock rose 2.4 per cent on the BSE on Thursday following an investor presentation outlining its growth plans for the next three to five years. Zaynich (or WCK 5222) is a key research candidate in Wockhardt's pipeline. It has completed global Phase 3 clinical trials, demonstrating a 20 per cent higher (statistically superior) composite cure rate compared to Meropenem, the current gold standard in antibiotics. Wockhardt claims Zaynich is the first new class of antibiotic in over 30 years to treat gram-negative infections. The drug has already saved 51 lives under compassionate use, including three in the US, where patients had failed all existing therapies. Zaynich is indicated for complicated urinary tract infections (UTIs), hospital-acquired and ventilator-associated bacterial pneumonia, bloodstream infections, and complicated intra-abdominal infections. The company expects approval from the Drugs Controller General of India (DCGI) shortly and plans to launch the drug in the second half of this financial year. Wockhardt has completed a pre-NDA (New Drug Application) meeting with the US Food and Drug Administration (USFDA) in May and plans to file in Q2FY26, targeting a potential launch in FY27. Regulatory filings in the EU and emerging markets are scheduled for the second half of FY26. Wockhardt estimates that around 1.1 million patients in India may benefit from Zaynich, while 371,000 carbapenem-resistant cases in the US and Europe are potential candidates. Overall, there are 4.3 million hospitalised cases involving key gram-negative pathogens in the US and EU. The firm sees a combined addressable patient pool of 2 million across India, the US, Europe, and China. Apart from Zaynich, Wockhardt is also betting on other antibiotics in its portfolio, such as Miqnaf (Nafithromycin), and its biotechnology portfolio, including insulin products. Miqnaf, already launched in India, treats community-acquired bacterial pneumonia (CABP) and upper respiratory tract infections. It has received Qualified Infectious Disease Product (QIDP) status from the USFDA, signifying unmet medical need, and Breakthrough Medicinal Product (BMP) designation in Saudi Arabia. Miqnaf targets a ₹10,800-crore market in India, with over 96 million potential prescriptions. In the biosimilars segment, Wockhardt is focusing on diabetes care and sees significant opportunity arising as Danish major Novo Nordisk phases out human insulin cartridges. This creates a ₹450-crore opportunity in India and a $157-million market across emerging economies. With only three major players in India, including itself, Wockhardt expects to benefit substantially. The company is doubling its diabetes biosimilars capacity over the next three years to meet growing demand, targeting business growth of 20–25 per cent.